Sun Pharma’s Q1 profit dropped due to an exceptional charge, though strong sales growth was seen across global markets.

• Profit before exceptional items rose 16.6% YoY to Rs 3,990.8 crore; EBITDA grew 19.2% with a 31.1% margin.
• India and US formulation sales grew 13.9% YoY each, together forming over 63% of total Q1 consolidated sales.
• Global Innovative Medicines and RoW markets showed robust double-digit growth, supporting overall revenue momentum.